What the research found
GLP-1 medications (semaglutide, tirzepatide and similar compounds) work by mimicking a naturally occurring gut hormone that signals satiety to the brain—but at much higher and more sustained levels than your body produces. While your endogenous GLP-1 breaks down within minutes, pharmaceutical versions remain active for about a week, reducing both hunger signals and the reward-driven drive to eat. This dual mechanism appears to affect not just caloric intake but also preoccupation with food itself.
Real-world weight loss outcomes vary considerably between individuals. Controlled trials show losses of 5–18% of body weight over 12–18 months, though actual practice typically yields lower figures: around 8% for people with type 2 diabetes and 11% without, after roughly a year. Weight loss is fastest in the first six months and plateaus thereafter. Critically, when people discontinue GLP-1s, approximately two-thirds of lost weight returns within a year in many cases—though adherence data suggests most users stop within 1–2 years anyway.
The health benefits documented in trials extend beyond weight loss alone. Users with obesity or related conditions show reduced cardiovascular events, improvements in kidney disease progression and fatty liver disease, partial resolution of sleep apnoea, and lower risk of prediabetes advancing to type 2 diabetes. Some benefits, including better HbA1c control, appear independent of weight reduction.
Why it matters for you
If you're using or considering GLP-1 therapy, the evidence suggests it's a tool—not a solution on its own. The medication addresses appetite regulation, but the habits you build during treatment (structured eating, consistent training, sleep hygiene) become the primary determinant of whether weight stays off long-term. This aligns with why MyKine users track biomarkers: GLP-1 can shift your metabolic state, but it won't preserve muscle or bone mass without adequate protein intake and resistance training. The source emphasises that typical clinical trials included structured nutrition support; if you're self-managing, seeking dietitian guidance strengthens outcomes.
For tracking purposes, realistic expectations matter. A 5% weight loss shift is clinically meaningful for cardiometabolic health—and this is often achievable—but regain is common after stopping. If you're tracking HbA1c, blood lipids, or inflammatory markers, you may see improvements that precede visible weight loss, offering early feedback that the medication is working even if the scale moves slowly. The recommended loss rate of 0.5–1 kg per week aligns with preserving lean mass, something users concerned with training performance should prioritise.
There is no specific "GLP-1 diet." Standard macronutrient and micronutrient guidance applies; the adjustment is portion-based rather than compositional. Calorie targets remain individual (based on your baseline and goals), though floors of 1,200 (women) and 1,800 (men) calories are advised to avoid nutritional insufficiency.
Caveats
- Claims about "natural GLP-1" from foods or supplements don't translate to the pharmacological dose or duration achieved by medication.
- Long-term outcomes beyond 2 years are limited; most data cover 12–18 months of active use.
- Individual response varies widely; some users see minimal weight loss despite adherence.
- Benefits in cardiovascular and metabolic markers are strongest in people with existing obesity or type 2 diabetes; applicability to lean or healthy-weight users is not established.
- The source emphasises GLP-1s are licensed as adjuncts to diet and exercise, not replacements—many real-world prescriptions omit this structured support, making outcomes less predictable.